Skip to main content

Pluripotency Assays

Quick Facts

FeatureInformation
PurposeFunctional Validation of Pluripotent Stem Cells
Applicable CellsiPSCs, hESCs, mESCs
Main GoalDemonstrate Self-Renewal and Trilineage Differentiation
CategoriesIn Vitro and In Vivo Assays
Biosafety LevelDepends on Cell Type

Overview

Pluripotency assays are experimental methods used to determine whether pluripotent stem cells possess the ability to generate derivatives of all three embryonic germ layers:

  • Ectoderm
  • Mesoderm
  • Endoderm

Unlike morphology or marker expression, pluripotency assays provide functional evidence that a stem cell line has retained developmental potential.

These assays are routinely used for:

  • iPSC characterization
  • hESC validation
  • Cell bank quality control
  • Disease modeling
  • Regenerative medicine research

Categories of Pluripotency Assays

Pluripotency can be evaluated using both in vitro and in vivo methods.

In VitroIn Vivo
Marker expressionTeratoma assay
Embryoid body formationChimera formation (mESCs)
Directed trilineage differentiation
PluriTest
ScoreCard assay

Hierarchy of Evidence

Different assays provide different levels of confidence.

Morphology

Marker Expression

Embryoid Body Formation

Directed Trilineage Differentiation

Teratoma Assay

Marker-Based Assessment

The simplest assessment of pluripotency involves detection of characteristic transcription factors and surface markers.

Common markers include:

  • OCT4
  • SOX2
  • NANOG
  • TRA-1-60
  • TRA-1-81
  • SSEA-4 (human)
  • SSEA-1 (mouse)

Although routinely performed, marker expression alone is not sufficient to demonstrate functional pluripotency.


Embryoid Body Assay

Embryoid bodies (EBs) are three-dimensional aggregates formed by pluripotent stem cells under non-self-renewing conditions.

Within the aggregate, spontaneous differentiation generates derivatives of all three germ layers.

Typical analyses include expression of lineage-specific markers for:

  • Ectoderm
  • Mesoderm
  • Endoderm

Advantages

  • Simple
  • Cost-effective
  • Widely used

Limitations

  • Variable differentiation
  • Difficult to quantify
  • Batch-to-batch variability

Directed Trilineage Differentiation

Rather than allowing spontaneous differentiation, cells are directed separately toward ectoderm, mesoderm, and endoderm using defined differentiation protocols.

Because each lineage is induced independently, this approach provides more reproducible and quantitative assessment than embryoid body formation.

Advantages

  • Highly reproducible
  • Quantitative
  • Publication standard
  • Animal-free

Limitations

  • More labor intensive
  • Requires optimized differentiation protocols

Teratoma Assay

Historically regarded as the gold standard for demonstrating pluripotency.

Pluripotent stem cells are transplanted into immunodeficient mice, where they form teratomas containing tissues derived from all three germ layers.

Although highly informative, ethical concerns and advances in in vitro assays have reduced its routine use.

Advantages

  • Strong evidence of developmental potential

Limitations

  • Animal use
  • Expensive
  • Time consuming
  • Ethical considerations

Chimera Formation Assay

Used exclusively for mouse embryonic stem cells.

Following blastocyst injection, pluripotent cells contribute to multiple tissues of the developing embryo and may contribute to the germline.

This remains the highest functional demonstration of pluripotency in mouse ESCs.


Computational Pluripotency Assays

PluriTest

PluriTest compares global gene expression profiles against reference datasets of pluripotent stem cells to generate a pluripotency score.

Advantages

  • Animal-free
  • High throughput
  • Highly reproducible

Limitations

  • Indirect assessment
  • Does not directly measure differentiation potential

ScoreCard Assay

The ScoreCard assay is a qPCR-based method that simultaneously measures:

  • Pluripotency genes
  • Ectoderm markers
  • Mesoderm markers
  • Endoderm markers

It is commonly used for rapid comparison of iPSC clones.


Emerging Approaches

Modern laboratories increasingly supplement classical assays with genome-wide analyses, including:

  • RNA sequencing
  • Single-cell RNA sequencing
  • DNA methylation profiling
  • ATAC-seq
  • Multiomics approaches

These methods provide additional insight into pluripotency, lineage bias, and epigenetic memory.


Choosing the Appropriate Assay

ApplicationRecommended Assay
Routine cultureMarker expression
Basic pluripotency validationEmbryoid body assay
Publication-quality characterizationDirected trilineage differentiation
Historical gold standardTeratoma assay
Mouse ESC validationChimera formation
High-throughput screeningPluriTest / ScoreCard

Advantages

  • Functional assessment of pluripotency
  • Supports quality control
  • Confirms developmental potential
  • Essential for stem cell characterization
  • Enables comparison between pluripotent cell lines

Limitations

  • No single assay is sufficient for all applications
  • Functional assays require additional time and resources
  • Some methods show experimental variability
  • In vivo assays raise ethical and regulatory concerns

Key Takeaways

  • Functional assays provide stronger evidence of pluripotency than morphology or marker expression alone.
  • Directed trilineage differentiation is now the preferred in vitro standard for validating pluripotent stem cells.
  • Teratoma formation remains historically important but is increasingly being replaced by standardized in vitro assays.
  • Computational approaches such as PluriTest and ScoreCard complement traditional biological assays but do not replace functional differentiation studies.

References

  • Müller FJ et al. A bioinformatic assay for pluripotency in human cells. Nature Methods (2011).
  • Bock C et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization. Cell (2011).
  • International Stem Cell Initiative recommendations.
  • Andrews PW et al. Assessing pluripotency and differentiation potential. Cell Stem Cell (2017).